<DOC>
	<DOCNO>NCT02045901</DOCNO>
	<brief_summary>The primary objective study compare efficacy Diclegis treatment nausea vomit pregnancy ( NVP ) pregnant adolescent age 12 17 year placebo . The secondary objective study compare safety Diclegis pregnant adolescent age 12 17 year placebo assess difference severity occurrence maternal adverse event ( AEs ) .</brief_summary>
	<brief_title>A Multicenter Trial Efficacy Safety Diclegis® Nausea Vomiting Pregnancy Pregnant Adolescents</brief_title>
	<detailed_description>This multicenter study treatment NVP actively recruit pregnant adolescent approximately 14-16 study site United States . After obtain informed consent Day 1 , medical examination conduct ensure eligibility . Participants randomize receive Diclegis placebo . On Day 1 , participant take 2 tablet study drug bedtime . On Days 2 14 , participant take 2 tablet study drug bedtime . The minimum dosage 2 tablet daily bedtime , increase , indicate , maximal dosage 4 tablet per day Days 3 14 . Participants require complete diary daily ass severity NVP use validated Pregnancy Unique Quantification Emesis ( PUQE ) record AEs experience ; Global Assessment Well scale complete Days 1 , 8 15 . Participants receive telephone call daily ass whether current dose regimen sufficient relieve NVP symptom , review study procedure , address questions/concerns . Participants return clinic evaluation Day 4 ( ±1 day ) Day 15 ( ±1 day ) end study visit . Eligible participant 12 17 year age , pregnant gestational age 7 15 week + 0 day , suffer NVP , PUQE score ≥6 , respond conservative management consist dietary/lifestyle advice accord 2004 American College Obstetrics Gynecology ( ACOG ) Practice Bulletin .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Morning Sickness</mesh_term>
	<mesh_term>Dicyclomine , doxylamine , pyridoxine drug combination</mesh_term>
	<mesh_term>Doxylamine</mesh_term>
	<mesh_term>Dicyclomine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>1 . The participant pregnant female follow age : least 12 year day recruitment ( ie , Day 1 ) yet 18 year last day study ( ie , Day 15 ) . 2 . The participant must provide write informed consent and/or assent participate study , agree follow dose instruction complete require study visit . 3 . The participant 's entry ultrasound indicate viable pregnancy confirm gestational age fetus 715 week + 0 day anticipate time first dose study drug provide NVP symptom begin &lt; /= 10 week gestation . If ultrasound perform within 4 week study entry visit , result obtain , additional ultrasound necessary . 4 . The participant suffering NVP PUQE score ≥6 . 5 . The participant respond conservative management consist dietary/lifestyle advice accord 2004 ACOG Practice Bulletin . 6 . The participant agree , multivitamin , continue current dose multivitamin duration trial . 7 . The participant plan termination pregnancy . 8 . On basis medical history , physical examination screen laboratory test , participant judge good health . 9 . The participant must able swallow study drug whole ( ie , without splitting , crush , chew tablet ) . 1 . The investigator confirm participant 's nausea vomit etiology NVP . 2 . The participant gestational trophoblastic disease multifetal gestation . 3 . The participant condition antihistamine , opinion investigator , contraindicate ( eg , epilepsy , alcoholism , glaucoma , chronic lung disease , urinary retention , heart block ) . 4 . The participant know hypersensitivity doxylamine succinate ethanolamine derivative antihistamine , pyridoxine hydrochloride , inactive ingredient Diclegis placebo formulation . 5 . The participant take monoamine oxidase inhibitor . 6 . The participant use antihistamine , anticholinergic , dopamine antagonist , serotonin antagonist , ginger , antiemetic therapy ( include acupressure , acupuncture , homeopathic remedy , medical hypnosis , relief band ) treat NVP previous 48 hour plan study . 7 . The participant use drug anticholinergic activity ( eg , tricyclic antidepressant ) . 8 . The participant take multivitamin contain 10 mg vitamin B6 plan study . 9 . The participant take supplementary vitamin B6 addition multivitamin preparation plan study ( e.g , total vitamin B6 great 10 mg ) . 10 . The participant currently drink amount alcohol . 11 . The participant condition might interfere conduct study , opinion investigator . For example , Diclegis® use caution female asthma , increase intraocular pressure , narrow angle glaucoma , stenosing peptic ulcer , pyloroduodenal obstruction urinary bladderneck obstruction . 12 . The participant likely unable comply study procedure inadequate cognitive language skill . 13 . The participant receive investigational drug within 30 day enrollment study schedule receive investigational drug course study . 14 . The participant currently breastfeed .</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Diclegis</keyword>
	<keyword>Morning</keyword>
	<keyword>Sickness</keyword>
</DOC>